The results revealed that MS was 16.3 months in the PD-L1( +) subset and 7.3 months in the patients not expressing PD-L1 (P < 0.001) [224]. Few more prospective trials (NCT02359019 and NCT02403920) investigating Pembrolizumab with chemotherapy or Pembrolizumab with chemotherapy and radiotherapy for use in SCLC are ongoing. The gene discussed is CD274; the disease is small cell lung carcinoma.